Morgan Stanley’s Verrica Pharmaceuticals VRCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.6K | Sell |
3,201
-19,185
| -86% | -$120K | ﹤0.01% | 6831 |
|
|
2026
Q1 | $118K | Buy |
22,386
+377
| +2% | +$2.41K | ﹤0.01% | 6086 |
|
|
2025
Q4 | $183K | Buy |
22,009
+321
| +1% | +$1.78K | ﹤0.01% | 5962 |
|
|
2025
Q3 | $93.5K | Buy |
21,688
+19,061
| +726% | +$115K | ﹤0.01% | 6185 |
|
|
2025
Q2 | $13.9K | Sell |
2,627
-4,315
| -62% | -$23.2K | ﹤0.01% | 6770 |
|
|
2025
Q1 | $30.7K | Sell |
6,942
-29,237
| -81% | -$189K | ﹤0.01% | 6431 |
|
|
2024
Q4 | $253K | Buy |
36,179
+18,001
| +99% | +$198K | ﹤0.01% | 5701 |
|
|
2024
Q3 | $264K | Buy |
18,178
+9,684
| +114% | +$436K | ﹤0.01% | 5648 |
|
|
2024
Q2 | $619K | Sell |
8,494
-4,928
| -37% | -$379K | ﹤0.01% | 5191 |
|
|
2024
Q1 | $795K | Buy |
13,422
+2,291
| +21% | +$126K | ﹤0.01% | 5090 |
|
|
2023
Q4 | $815K | Sell |
11,131
-767
| -6% | -$31.5K | ﹤0.01% | 5036 |
|
|
2023
Q3 | $462K | Buy |
11,898
+7,130
| +150% | +$362K | ﹤0.01% | 5200 |
|
|
2023
Q2 | $275K | Sell |
4,768
-11,671
| -71% | -$709K | ﹤0.01% | 5501 |
|
|
2023
Q1 | $1.07M | Buy |
16,439
+15,113
| +1,140% | +$914K | ﹤0.01% | 4813 |
|
|
2022
Q4 | $36.5K | Sell |
1,326
-2,910
| -69% | -$77.7K | ﹤0.01% | 6426 |
|
|
2022
Q3 | $123K | Sell |
4,236
-5,173
| -55% | -$177K | ﹤0.01% | 5976 |
|
|
2022
Q2 | $181K | Sell |
9,409
-68,762
| -88% | -$3.46M | ﹤0.01% | 5953 |
|
|
2022
Q1 | $6.34M | Sell |
78,171
-12,928
| -14% | -$1.07M | ﹤0.01% | 3424 |
|
|
2021
Q4 | $8.35M | Buy |
91,099
+86,641
| +1,943% | +$9.81M | ﹤0.01% | 3142 |
|
|
2021
Q3 | $556K | Sell |
4,458
-7,749
| -63% | -$869K | ﹤0.01% | 5426 |
|
|
2021
Q2 | $1.38M | Buy |
12,207
+11,745
| +2,542% | +$1.42M | ﹤0.01% | 4896 |
|
|
2021
Q1 | $70K | Sell |
462
-905
| -66% | -$125K | ﹤0.01% | 6195 |
|
|
2020
Q4 | $157K | Buy |
1,367
+806
| +144% | +$74.1K | ﹤0.01% | 5713 |
|
|
2020
Q3 | $43K | Sell |
561
-281
| -33% | -$23K | ﹤0.01% | 5775 |
|
|
2020
Q2 | $93K | Buy |
842
+288
| +52% | +$33.3K | ﹤0.01% | 5439 |
|
|
2020
Q1 | $61K | Sell |
554
-1,631
| -75% | -$215K | ﹤0.01% | 5390 |
|
|
2019
Q4 | $347K | Buy |
2,185
+1,793
| +457% | +$265K | ﹤0.01% | 5133 |
|
|
2019
Q3 | $58K | Buy |
392
+333
| +564% | +$37.1K | ﹤0.01% | 5661 |
|
|
2019
Q2 | $7K | Sell |
59
-174
| -75% | -$16.3K | ﹤0.01% | 6239 |
|
|
2019
Q1 | $25K | Sell |
233
-1,382
| -86% | -$159K | ﹤0.01% | 5943 |
|
|
2018
Q4 | $132K | Buy |
1,615
+495
| +44% | +$60.1K | ﹤0.01% | 5441 |
|
|
2018
Q3 | $182K | Buy |
1,120
+879
| +365% | +$150K | ﹤0.01% | 5498 |
|
|
2018
Q2 | $47K | Buy |
+241
| New | +$47.2K | ﹤0.01% | 5929 |
|
Other funds holding VRCA
CP
CC
AAA
VCIM
AC
BFM
Morgan Stanley's VRCA Position: Q2 2026 in Review
Morgan Stanley reduced its Verrica Pharmaceuticals (VRCA) stake by 86% in Q2 2026, selling an estimated $120K and leaving 3,201 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6831.
Morgan Stanley first reported a position in VRCA in Q2 2018 and has held it in 33 quarters since. The position peaked at $8.35M in Q4 2021. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.
- Morgan Stanley held 3,201 shares of Verrica Pharmaceuticals worth $19.6K as of Q2 2026.
- Morgan Stanley sold 19,185 Verrica Pharmaceuticals shares in Q2 2026, an estimated $120K.
- Verrica Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6831 holding.
- Morgan Stanley first reported a position in Verrica Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- Morgan Stanley's Verrica Pharmaceuticals position peaked at $8.35M in Q4 2021.
- 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.